Pfizer Can't Duck 10 Lipitor Diabetes Claims

By Emily Field (February 3, 2015, 8:09 PM EST) -- A South Carolina federal judge on Monday nixed Pfizer Inc.'s attempt to duck 10 cases in multidistrict litigation over claims that its cholesterol drug Lipitor can cause diabetes, saying that their Texas failure-to-warn claims aren't preempted by federal regulation.

U.S. District Judge Richard M. Gergel, presiding over the MDL, rejected Pfizer's argument that the Federal Food, Drug and Cosmetic Act preempts an exception to a Texas statute creating an affirmative defense that a pharmaceutical manufacturer isn't liable for failure-to-warn if Food And Drug Administration warnings accompany a product. According to the ruling, both Pfizer and the plaintiffs agree that the only...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!